DNA RNA and Cells
13 March 2013
Ceregene And Alzheimer’s Disease Cooperative Study Group Complete Enrollment Of CERE-110 Phase 2 Trial4 March 2013
Sarepta’s Marburg Drug Shows High Survival Rates After Intramuscular Delivery in Non-Human Primates26 February 2013
Isis Pharmaceuticals Initiates Phase 2 Study Of ISIS-CRP Rx In Patients With Atrial Fibrillation26 February 2013
United Therapeutics Moves Forward Towards a Phase I Study of Pluristem’s PLX-PAD Cells for Pulmonary Arterial Hypertension25 February 2013
Coronado Biosciences Announces Initiation of Investigator-Initiated Study Evaluating TSO in Psoriasis19 February 2013
Isis Initates Phase 2/3 Study Of ISIS-TTR Rx And Earns USD 7.5 Million Milestone Payment From GlaxoSmithKline15 February 2013
Gamida Cell’s NiCord Demonstrates Successful Engraftment in Patients with Hematological Malignancies in Phase I/II Study12 February 2013
International Stem Cell Corporation Demonstrates Positive Animal Efficacy Results in Metabolic Liver Disease Program11 February 2013
ACT’s Clinical Partner Receives FDA Approval to Initiate Clinical Trial Using the Company’s hESC-derived Cells to Treat Severe Myopia9 February 2013
RNL BIO filed Phase II/III Clinical Trial with KFDA to Treat Cerebral Palsy Using Autologous Fat Derived Stem Cells6 February 2013
First Patient Treated in Genelux Phase I Trial With GL-ONC1 at Memorial Sloan Kettering Cancer Center5 February 2013
Regen BioPharma Files Investigational New Drug (IND) Application With FDA on HemaXellerate I(TM) Stem Cell Drug for Aplastic Anemia5 February 2013
Hemispherx Biopharma Receives Complete Response Letter From FDA on Ampligen(R) New Drug Application for Chronic Fatigue Syndrome4 February 2013
International Stem Cell Corporation Announces Positive Results From In Vivo Animal Study of Parkinson’s Disease31 January 2013
Arteriocyte Receives FDA Approval to Initiate Cellular Therapy Trial for Treatment of Thermal Burn Wounds in Wounded Warriors30 January 2013
RXi Pharmaceuticals Announces Completion of Enrollment in Second Phase 1 Trial for RXI-109 Program30 January 2013
Mesoblast Receives FDA Clearance for Phase 2 Clinical Trial of Mesenchymal Precursor Cells in Patients With Active Rheumatoid ArthritisNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports